A 52-week Randomized, Double-blind, Placebo-controlled, Multi-center Phase 2b Study With a 52-week Blinded Extension Assessing Safety and Efficacy of Frexalimab, a CD40L-antagonist Monoclonal Antibody, for Preservation of Pancreatic β-cell Function in Adults and Adolescents With Newly Diagnosed Type 1 Diabetes on Insulin Therapy
Latest Information Update: 25 May 2025
At a glance
- Drugs Frexalimab (Primary) ; Insulin (Primary)
- Indications Type 1 diabetes mellitus
- Focus Proof of concept; Therapeutic Use
- Acronyms FABULINUS
- Sponsors Sanofi
Most Recent Events
- 24 Jun 2024 Trial design presented at the 84th Annual Scientific Sessions of the American Diabetes Association.
- 01 Feb 2024 According to a Sanofi media release, first participant has been treated.
- 20 Dec 2023 Planned End Date changed from 31 Oct 2028 to 27 Oct 2028.